Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2016 | original report | Ausgabe 3/2016

memo - Magazine of European Medical Oncology 3/2016

Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2016
Autoren:
Georgi Mihaylov, Zhasmina Mihaylova, Lubos Drgona, Andrea Cipkova, Jan Novak, Roumyana Petrova
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi: 10.​1007/​s12254-016-0279-z) contains supplementary material, which is available to authorized users.
Prior conference presentations: Mihaylov G, Mihaylova Z, Drgona L, Cipkova A, Novak J, Petrova R. Healthcare resource utilization (HCRU) in hospitalized febrile neutropenia (FN) patients treated with chemotherapy for solid tumors (ST) and hematological malignancies (HM) in Bulgaria (BG), Czech Republic (CZ) and Slovakia (SK) as observed in clinical practice. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8–12 November 2014; abstract and poster code PCN245. Gercheva L, Goranov S, Raynov J, Mihaylova Z, Mihaylov G, Karanikolov S, Petrova R. Healthcare resource utilization (HCRU) in hospitalized febrile neutropenia (FN) patients treated with chemotherapy for solid tumors (ST) and hematological malignancies (HM) in Bulgaria. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8–12 November 2014; abstract and poster code PCN238

Summary

Background

Febrile neutropenia (FN) is a common side effect of chemotherapy that frequently necessitates hospitalization and healthcare resource utilization (HCRU), but is poorly studied in Eastern European countries. We investigated HCRU and granulocyte colony-stimulating factor (G-CSF) use in patients hospitalized for FN in Bulgaria, Czech Republic, and Slovakia.

Patients and methods

This was a multicenter retrospective cohort study. Eligible patients were ≥18 years old, had received chemotherapy for solid tumors or hematological malignancies of any stage, and had been hospitalized for FN. The primary objective was to evaluate FN-related HCRU; secondary objectives included the description of chemotherapy treatment patterns and G‑CSF use. Data were analyzed by participating country.

Results

Data of 156 patients from Bulgaria and 79 patients each from the Czech Republic and Slovakia were analyzed. The most frequent solid tumors were breast (n = 28) and testicular cancer (n = 13), and the most common hematological malignancies were non-Hodgkin B‑cell lymphoma (n = 51) and acute myeloid leukemia (n = 35). In general, G‑CSF was used to treat FN rather than as prophylaxis. Most patients had a single FN episode, predominantly in cycle 1. The mean duration of FN-related hospitalization was 7–9 days, with longer stays in patients with hematological malignancies.

Conclusions

Results indicate considerable FN-related HCRU in all countries. Frequent lack of G‑CSF primary prophylaxis was observed, particularly in Slovakia.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Zusatzmaterial
Nur für berechtigte Nutzer zugänglich
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

memo - Magazine of European Medical Oncology 3/2016 Zur Ausgabe